FIGURE 3.

Treatment algorithm for advanced NSCLC. Advanced NSCLC consists of metastatic NSCLC and unresectable locally advanced NSCLC. EGFR, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, MET, RET, and PD‐L1 expressions are included in the molecular testing. For patients without targetable mutations, pembrolizumab + carboplatin + (nab‐) paclitaxel is recommended. ^†For patients with EGFR exon 19 deletion or exon 21 L858R, erlotinib, afatinib, gefitinib, and dacomitinib are also recommended. However, when the disease progresses on these TKIs, patients are recommended for a second molecular testing for T790M mutation test. ^‡Patients who are intolerant to crizotinib may be switched to ceritinib, alectinib, or brigatinib. ^§Entrectinib is recommended for patients with CNS metastasis. ^¶Single‐agent vemurafenib is a treatment option if the combination of dabrafenib + trametinib is not tolerated